Protandim®

Search documents
LifeVantage Announces Closing of LoveBiome Acquisition
Globenewswire· 2025-10-02 12:00
Strategic acquisition strengthens leadership position in direct sales and gut and microbiome health marketSALT LAKE CITY, Oct. 02, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the closing of its previously announced acquisition of LoveBiome, a pioneering direct sales company dedicated to comprehensive microbiome care and wellness solutions. Under the term ...
LifeVantage to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
Globenewswire· 2025-09-22 12:00
Group 1 - LifeVantage Corporation will participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025, with CEO Steve Fife and CFO Carl Aure presenting [1][2] - The presentation is scheduled for approximately 11:00 a.m. Eastern Time and will be available via a live webcast on the company's Investor Relations website [2] - LifeVantage specializes in nutrigenomics, offering products that activate health processes at the cellular level, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [3] Group 2 - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, focusing on health and wellness products that work with individual biology [3] - The company also provides a business opportunity for independent consultants to sell its products and promote entrepreneurship [3]
LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2025
Globenewswire· 2025-09-04 20:05
Core Insights - LifeVantage Corporation reported a strong financial performance for the fourth quarter and full fiscal year 2025, with a revenue growth of approximately 13% to $55.1 million in Q4 and 14.2% to $228.5 million for the full year [6][9][14] - The international business showed growth for the first time in nearly three years, particularly in the Asia/Pacific and Europe regions, which increased by approximately 8% [6][9] - The company has a strong balance sheet with $20.2 million in cash and no debt, positioning it well for future growth [22] Fourth Quarter Fiscal 2025 Summary - Revenue for Q4 was $55.1 million, a 12.6% increase year-over-year, with a 14.1% increase in the Americas and a 7.6% increase in Asia/Pacific & Europe [7][9] - Gross profit was $44.0 million, representing 79.9% of revenue, compared to 79.5% in Q4 fiscal 2024 [8] - Net income for Q4 was $2.0 million, or $0.15 per diluted share, up from $1.3 million, or $0.10 per diluted share in the prior year [12][9] Fiscal Year 2025 Summary - Total revenue for fiscal 2025 was $228.5 million, a 14.2% increase from $200.2 million in fiscal 2024 [14] - Gross profit for the year was $183.7 million, or 80.4% of revenue, compared to 79.3% in fiscal 2024 [15] - Net income for the year was $9.8 million, or $0.75 per diluted share, compared to $2.9 million, or $0.23 per diluted share in fiscal 2024 [19] Share Repurchase and Dividend - The company repurchased 0.3 million shares for $3.1 million during fiscal 2025, with approximately $17.3 million remaining under the current repurchase program [21] - A cash dividend of $0.045 per common share was declared, to be paid on September 16, 2025 [23] Fiscal Year 2026 Guidance - LifeVantage expects revenue in the range of $225 million to $240 million for fiscal 2026, with adjusted EBITDA of $23 million to $26 million [24]
LifeVantage Announces Acquisition of LoveBiome, Expanding Leadership in Direct Sales, Microbiome Health and Wellness
Globenewswire· 2025-09-03 21:00
Core Insights - LifeVantage Corporation has announced a definitive agreement to acquire LoveBiome, a direct sales company focused on microbiome health solutions, enhancing its position in the gut health market [1][3] - The acquisition aligns with LifeVantage's mission to activate optimal health processes and expand its product offerings in the growing gut health sector [1][5] - The global gut health supplement market is projected to grow from $14.4 billion in 2025 to $32.4 billion by 2035, with a robust CAGR of 8.4% [5] Company Strategy - The acquisition of LoveBiome is seen as a strategic move to enhance LifeVantage's Activation differentiation and broaden its community reach [1][5] - LifeVantage aims to leverage LoveBiome's expertise in microbiome science to complement its existing product portfolio, including the Protandim® family and MindBody GLP-1 System™ [1][5] - The integration of LoveBiome's innovative P84 product is expected to strengthen LifeVantage's offerings in gut health, which is increasingly recognized for its impact on overall wellness [1][5] Transaction Details - LifeVantage will acquire LoveBiome's critical operating assets and retain key personnel, including founder Kelly Olsen, to ensure operational continuity [3] - The acquisition is expected to close by mid-October, pending customary closing conditions and regulatory approvals [3] - The transaction is anticipated to enhance revenue growth and be accretive to Adjusted EPS and Adjusted EBITDA in the first year, with additional synergy opportunities [5]
LifeVantage to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Globenewswire· 2025-09-02 20:05
Core Insights - LifeVantage Corporation will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York [1] - The company's President and CEO, Steve Fife, along with CFO Carl Aure, will present to investors on September 10, 2025, at approximately 1:00 p.m. Eastern Time [2] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can activate health at the cellular level [3] - The company offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and the MindBody GLP-1 System™, among others [3] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah, with a business model that includes independent consultants selling products and sharing business opportunities [3]
LifeVantage to Announce Fourth Quarter and Full Fiscal Year 2025 Results on September 4, 2025
Globenewswire· 2025-08-21 20:05
Core Insights - LifeVantage Corporation will release its financial results for the fourth quarter and full fiscal year ended June 30, 2025, on September 4, 2025, after market close [1] - A conference call for investors will take place on the same day at 2:30 p.m. Mountain Time [1] Financial Results Announcement - The financial results will cover the fourth quarter and the full fiscal year ending June 30, 2025 [1] - The announcement will be made after the stock market closes on September 4, 2025 [1] Conference Call Details - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and will last until September 18, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days [3] Company Overview - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health at the cellular level [4] - The company offers a range of products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] - LifeVantage was founded in 2003 and is headquartered in Lehi, Utah [4]
LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡
GlobeNewswire News Room· 2025-07-22 12:00
Core Insights - LifeVantage Corporation announced new results from its second human clinical study on the MindBody GLP-1 System™, showing significant improvements in GLP-1 levels and related health outcomes [1][2] Clinical Study Results - The average increase in GLP-1 production improved to over 200%, up from a previously reported 140% [2] - Participants experienced an average weight loss of 11 pounds within 12 weeks, with some losing up to 25 pounds [6] - There was a reported decrease in total body fat percentage of up to 9% and a decrease in visceral fat of up to 24% [6] - Participants reported a 100% weight loss from fat, not muscle, and a 6% increase in skeletal muscle [6] Behavioral Changes - 95% of participants reported decreased sugar cravings, while 89% reported decreased fast-food cravings [6] - 85% of participants indicated they now eat for health instead of emotions, and 81% reported an increased ability to resist snacking [6] - 89% of participants ate less at meals, and 86% reported feeling less hungry [6] Company Background - LifeVantage Corporation is a pioneer in nutrigenomics, focusing on how nutrition and natural compounds can enhance health [5] - The company offers a range of products, including the MindBody GLP-1 System™, aimed at promoting optimal health at the cellular level [5]
LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025
Globenewswire· 2025-05-06 20:05
Core Viewpoint - LifeVantage Corporation reported strong financial results for the third fiscal quarter of 2025, with a significant increase in revenue and profitability, driven by robust demand for its products and international expansion efforts [4][5]. Financial Performance - Revenue for the third quarter ended March 31, 2025, was $58.4 million, representing a 21.1% increase year-over-year. Excluding foreign currency fluctuations, revenue increased by 22.1% [5][9]. - Gross profit for the quarter was $47.3 million, or 81.0% of revenue, compared to 78.9% in the same period of fiscal 2024, attributed to a favorable product sales mix and reduced inventory costs [6]. - Adjusted EBITDA rose by 27% to $6.4 million from $5.1 million a year ago [9][12]. - Net income for the quarter was $3.5 million, or $0.26 per diluted share, compared to $1.7 million, or $0.13 per diluted share, in the prior year [11][9]. Regional Performance - Revenue in the Americas increased by 29.5%, with a notable 31.4% rise in the United States. Conversely, revenue in the Asia/Pacific & Europe region decreased by 7.2%, with a constant currency decline of approximately 4.7% [5][9]. Operational Highlights - The company launched its Evolve Compensation Plan in several Asian markets and introduced the MindBody GLP-1 System™ in multiple international regions, indicating a strategic focus on global market expansion [4]. - Active Independent Consultants increased by 6.1% to 52,000, with a 12.9% rise in the Americas, while the Asia/Pacific & Europe region saw a decline of 5.6% [32]. Balance Sheet and Liquidity - Cash and cash equivalents as of March 31, 2025, were $22.5 million, up from $16.9 million at the end of June 2024, with no debt outstanding [13]. - The company generated $10.8 million in cash from operations during the first nine months of fiscal 2025, compared to $9.6 million in the same period of fiscal 2024 [13]. Shareholder Returns - LifeVantage declared a cash dividend of $0.045 per common share, scheduled for payment on June 13, 2025 [15]. Fiscal Year Guidance - The company expects revenue for fiscal year 2025 to be in the range of $228 million to $235 million, with adjusted EBITDA guidance of $21 million to $24 million and adjusted earnings per share between $0.72 and $0.88 [16].
LifeVantage to Announce Third Quarter Fiscal Year 2025 Results on May 6, 2025
Globenewswire· 2025-04-22 20:05
Company Overview - LifeVantage Corporation (Nasdaq: LFVN) is a leading health and wellness company focused on activating optimal health processes at the cellular level [1] - The company specializes in nutrigenomics, which studies how nutrition and naturally occurring compounds can unlock genetic health [4] - LifeVantage offers a range of scientifically validated products, including the Protandim® family, TrueScience® Liquid Collagen, and various health-supporting nutrients [4] Upcoming Financial Results - LifeVantage will release its financial results for the third quarter ended March 31, 2025, after the stock market closes on May 6, 2025 [1] - A conference call for investors is scheduled for 2:30 p.m. Mountain Time (4:30 p.m. Eastern Time) on the same day [1] Investor Participation - Investors can participate in the live call by dialing (877) 704-4453 from the U.S. or (201) 389-0920 for international callers [2] - A telephone replay will be available approximately two hours after the call and can be accessed until May 20, 2025 [2] Webcast Information - A live webcast of the conference call will be available on the Investor Relations section of the company's website [3] - The webcast will be archived for approximately 30 days for later access [3]